Rockefeller Capital Management
INMB icon

Rockefeller Capital Management’s INmune Bio INMB Stock Holding History

Rockefeller Capital Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.83K Hold
2,500
– – ﹤0.01% 4354
2025
Q4 		$3.9K Hold
2,500
– – ﹤0.01% 4144
2025
Q3 		$5.17K Buy
+2,500
New +$5.72K ﹤0.01% 3860
2024
Q1 		– Sell
-18,220
Closed -$205K – 1699
2023
Q4 		$205K Buy
+18,220
New +$153K ﹤0.01% 1530
2020
Q3 		– Sell
-50
Closed – – 2680
2020
Q2 		$0 Buy
+50
New +$252 ﹤0.01% 2626

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rockefeller Capital Management's INMB Position: Q1 2026 in Review

Rockefeller Capital Management held its INmune Bio (INMB) position steady in Q1 2026 at 2,500 shares worth $2.83K. The position accounts for ﹤0.01% of the portfolio, ranked #4354.

Rockefeller Capital Management first reported a position in INMB in Q2 2020 and has held it in 5 quarters since. The position peaked at $205K in Q4 2023. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Rockefeller Capital Management held 2,500 shares of INmune Bio worth $2.83K as of Q1 2026.
  • Rockefeller Capital Management left its INmune Bio share count unchanged in Q1 2026.
  • INmune Bio made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4354 holding.
  • Rockefeller Capital Management first reported a position in INmune Bio in Q2 2020 and has held it in 5 quarters since.
  • Rockefeller Capital Management's INmune Bio position peaked at $205K in Q4 2023.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.